Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2012

Open Access 01-12-2012 | Review

The role of A20 in the pathogenesis of lymphocytic malignancy

Authors: Fan Zhang, Lijiang Yang, Yangqiu Li

Published in: Cancer Cell International | Issue 1/2012

Login to get access

Abstract

Autoimmune phenomena were identified in many different cases of hematological diseases and solid tumors, which may be due to alterations in the expression and function of the NF-κB signaling pathway. Recently, a number of studies have shown that the deletion or mutation of A20, a negative regulator of NF-κB, is frequently found in lymphomas, suggesting that it may be a linker between the altered immune response and leukemogenesis. The aim of this review is to summarize current findings of the A20 biological functions and its molecular mechanism as a tumor suppressor and immune regulator. The identification of A20 mutations and deletions in lymphocytic malignancy and the predictive significance of these aberrations are also reviewed.
Appendix
Available only for authorised users
Literature
1.
Chanudet E, Huang Y, Zeng N, Streubel B, Chott A, Raderer M, Du M-Q: TNFAIP3 abnormalities in MALT lymphoma with autoimmunity. B J Haematol. 2011, 154 (4): 533-535. 10.1111/j.1365-2141.2011.08623.x.CrossRef
2.
Opipari AW, Boguski MS, Dixit VM: The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J B Chem. 1990, 265 (25): 14705-14708.
3.
Dixit VM, Green S, Sarma V, Holzman LB, Wolf FW, O'Rourke K, Ward PA, Prochownik EV, Marks RM: Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J B chem. 1990, 265 (5): 2973-2978.
4.
Tewari M, Wolf FW, Seldin MF, O'Shea KS, Dixit VM, Turka LA: Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J Immunol. 1995, 154 (4): 1699-1706.PubMed
5.
Vereecke L, Beyaert R, van Loo G: The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009, 30 (8): 383-391. 10.1016/j.it.2009.05.007.CrossRefPubMed
6.
Hymowitz SG, Wertz IE: A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer. 2010, 10 (5): 332-341. 10.1038/nrc2775.CrossRefPubMed
7.
Evans PC, Ovaa H, Hamon M, Kilshaw PJ, Hamm S, Bauer S, Ploegh HL, Smith TS: Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J. 2004, 378: 727-734. 10.1042/BJ20031377.PubMedCentralCrossRefPubMed
8.
Wertz IE, O'Rourke KM, Zhou HL, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappa B signalling. Nature. 2004, 430 (7000): 694-699. 10.1038/nature02794.CrossRefPubMed
9.
Bosanac I, Wertz IE, Pan B, Yu C, Kusam S, Lam C, Phu L, Phung Q, Maurer B, Arnott D: Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling. Mol Cell. 2010, 40 (4): 548-557. 10.1016/j.molcel.2010.10.009.CrossRefPubMed
10.
Beyaert R, Heyninck K, Van Huffel S: A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol. 2000, 60 (8): 1143-1151. 10.1016/S0006-2952(00)00404-4.CrossRefPubMed
11.
Opipari AW, Hu HM, Yabkowitz R, Dixit VM: The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem. 1992, 267 (18): 12424-12427.PubMed
12.
Jaattela M, Mouritzen H, Elling F, Bastholm L: A20 zinc finger protein inhibits TNF and IL-1 signaling. J Immunol. 1996, 156 (3): 1166-1173.PubMed
13.
Song HY, Rothe M, Goeddel DV: The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A. 1996, 93 (13): 6721-6725. 10.1073/pnas.93.13.6721.PubMedCentralCrossRefPubMed
14.
Krikos A, Laherty CD, Dixit VM: Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem. 1992, 267 (25): 17971-17976.PubMed
15.
Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C: A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. J Biol Chem. 1996, 271 (30): 18068-18073. 10.1074/jbc.271.30.18068.CrossRefPubMed
16.
Sarma V, Lin Z, Clark L, Rust BM, Tewari M, Noelle RJ, Dixit VM: Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem. 1995, 270 (21): 12343-12346. 10.1074/jbc.270.21.12343.CrossRefPubMed
17.
Laherty CD, Perkins ND, Dixit VM: Human T cell leukemia virus type I Tax and phorbol 12-myristate 13-acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor kappa B. J Biol Chem. 1993, 268 (7): 5032-5039.PubMed
18.
Miller WE, Mosialos G, Kieff E, Raab-Traub N: Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol. 1997, 71 (1): 586-594.PubMedCentralPubMed
19.
Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM: The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem. 1992, 267 (34): 24157-24160.PubMed
20.
Zhang SQ, Kovalenko A, Cantarella G, Wallach D: Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity. 2000, 12 (3): 301-311. 10.1016/S1074-7613(00)80183-1.CrossRefPubMed
21.
De Valck D, Heyninck K, Van Criekinge W, Vandenabeele P, Fiers W, Beyaert R: A20 inhibits NF-kappaB activation independently of binding to 14-3-3 proteins. Biochem Biophys Res Commun. 1997, 238 (2): 590-594. 10.1006/bbrc.1997.7343.CrossRefPubMed
22.
Ferran C, Stroka DM, Badrichani AZ, Cooper JT, Wrighton CJ, Soares M, Grey ST, Bach FH: A20 inhibits NF-kappaB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis. Blood. 1998, 91 (7): 2249-2258.PubMed
23.
Heyninck K, De Valck D, Vanden Berghe W, Van Criekinge W, Contreras R, Fiers W, Haegeman G, Beyaert R: The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol. 1999, 145 (7): 1471-1482. 10.1083/jcb.145.7.1471.PubMedCentralCrossRefPubMed
24.
Liu YC, Penninger J, Karin M: Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol. 2005, 5 (12): 941-952. 10.1038/nri1731.CrossRefPubMed
25.
Düwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P, Krappmann D: A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol. 2009, 182 (12): 7718-7728. 10.4049/jimmunol.0803313.CrossRefPubMed
26.
Malinverni C, Unterreiner A, Staal J, Demeyer A, Galaup M, Luyten M, Beyaert R, Bornancin F: Cleavage by MALT1 induces cytosolic release of A20. Biochem Biophys Res Commun. 2010, 400 (4): 543-547. 10.1016/j.bbrc.2010.08.091.CrossRefPubMed
27.
Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley SC, Beyaert R: Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol. 2010, 80 (12): 2009-2020. 10.1016/j.bcp.2010.06.044.CrossRefPubMed
28.
Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J: Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009, 459 (7247): 712-716. 10.1038/nature07969.CrossRefPubMed
29.
Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R: T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol. 2008, 9 (3): 263-271. 10.1038/ni1561.CrossRefPubMed
30.
Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wojtowicz E, Soberon V, Schenten D, Mack B, Reutelshofer M: B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood. 2011, 117 (7): 2227-2236. 10.1182/blood-2010-09-306019.CrossRefPubMed
31.
Song XT, Evel-Kabler K, Shen L, Rollins L, Huang XF, Chen SY: A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med. 2008, 14 (3): 258-265. 10.1038/nm1721.PubMedCentralCrossRefPubMed
32.
Wang X, Friesen J, Nishanth G, Thi XN, Matuschewski K, Schluter D: Hepatocyte-specific knockout of A20 augments defense against malaria liver stage infections. Int J Med Microbiol. 2011, 301: 42-43.CrossRef
33.
Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A: Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009, 459 (7247): 717-721. 10.1038/nature07968.PubMedCentralCrossRefPubMed
34.
35.
Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD, Barford D: Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 2009, 10 (5): 466-473. 10.1038/embor.2009.55.PubMedCentralCrossRefPubMed
36.
Inomata M, Niida S, Shibata K, Into T: Regulation of Toll-like receptor signaling by NDP52-mediated selective autophagy is normally inactivated by A20. Cell Mol Life Sci. 2012, 69 (6): 963-979. 10.1007/s00018-011-0819-y.PubMedCentralCrossRefPubMed
37.
Shembade N, Harhaj E: A20 inhibition of NF-κB and inflammation: Targeting E2:E3 ubiquitin enzyme complexes. Cell Cycle. 2010, 9 (13): 10-11. 10.4161/cc.9.13.12269.CrossRef
38.
Shembade N, Harhaj NS, Parvatiyar K, Copeland NG, Jenkins NA, Matesic LE, Harhaj EW: The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat Immunol. 2008, 9 (3): 254-262. 10.1038/ni1563.CrossRefPubMed
39.
Bousquet M, Harris MH, Zhou BY, Lodish HF: MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci U S A. 2010, 107 (50): 21558-21563. 10.1073/pnas.1016611107.PubMedCentralCrossRefPubMed
40.
Guo SQ, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, Purton LE, Fleming HH, Cobb B, Merkenschlager M: MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci U S A. 2010, 107 (32): 14229-14234. 10.1073/pnas.0913574107.PubMedCentralCrossRefPubMed
41.
O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D: MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci U S A. 2010, 107 (32): 14235-14240. 10.1073/pnas.1009798107.PubMedCentralCrossRefPubMed
42.
Ooi AG, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY: MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci U S A. 2010, 107 (50): 21505-21510. 10.1073/pnas.1016218107.PubMedCentralCrossRefPubMed
43.
Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov KD, O'Connell RM, Baltimore D: MicroRNA-125b potentiates macrophage activation. J Immunol. 2011, 187 (10): 5062-5068. 10.4049/jimmunol.1102001.PubMedCentralCrossRefPubMed
44.
Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang DF, Aguiar RCT: MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappa B pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A. 2012, 109 (20): 7865-7870. 10.1073/pnas.1200081109.PubMedCentralCrossRefPubMed
45.
Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, Seto M: TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009, 114 (12): 2467-2475. 10.1182/blood-2008-12-194852.CrossRefPubMed
46.
Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E: The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood. 2009, 113 (20): 4918-4921. 10.1182/blood-2008-08-174110.PubMedCentralCrossRefPubMed
47.
Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S: TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009, 206 (5): 981-989. 10.1084/jem.20090528.PubMedCentralCrossRefPubMed
48.
Nakajima S, Saito Y, Takahashi S, Hiramatsu N, Kato H, Johno H, Yao J, Paton AW, Paton JC, Kitamura M: Anti-inflammatory subtilase cytotoxin up-regulates A20 through the unfolded protein response. Biochem Biophys Res Commun. 2010, 397 (2): 176-180. 10.1016/j.bbrc.2010.05.069.CrossRefPubMed
49.
Yan QG, Huang YX, Watkins AJ, Kocialkowski S, Zeng NY, Hamoudi RA, Isaacson PG, de Leval L, Wotherspoon A, Du MQ: BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica. 2012, 97 (4): 595-598. 10.3324/haematol.2011.054080.PubMedCentralCrossRefPubMed
50.
Chanudet E, Huang Y, Ichimura K, Dong G, Hamoudi RA, Radford J, Wotherspoon A, Isaacson PG, Ferry J, Du MQ: A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia. 2010, 24 (2): 488-489. 10.1038/leu.2009.278.CrossRef
51.
Braun FC, Grabarczyk P, Mobs M, Braun FK, Eberle J, Beyer M, Sterry W, Busse F, Schroder J, Delin M: Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sezary syndrome. Leukemia. 2011, 25 (9): 1494-1501. 10.1038/leu.2011.101.CrossRefPubMed
52.
Giulino L, Mathew S, Ballon G, Chadburn A, Barouk S, Antonicelli G, Leoncini L, Liu YF, Gogineni S, Tam W: A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma. Blood. 2011, 117 (18): 4852-4854. 10.1182/blood-2010-10-310995.PubMedCentralCrossRefPubMed
53.
Montesinos-Rongen M, Schmitz R, Brunn A, Gesk S, Richter J, Hong K, Wiestler OD, Siebert R, Kuppers R, Deckert M: Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol. 2010, 120 (4): 529-535. 10.1007/s00401-010-0709-7.CrossRefPubMed
54.
Philipp C, Edelmann J, Buhler A, Winkler D, Stilgenbauer S, Kuppers R: Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL. Int J Cancer. 2011, 128 (7): 1747-1750. 10.1002/ijc.25497.CrossRefPubMed
55.
Frenzel LP, Claus R, Plume N, Schwamb J, Konermann C, Pallasch CP, Claasen J, Brinker R, Wollnik B, Plass C: Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus. Int J Cancer. 2011, 128 (10): 2495-2500. 10.1002/ijc.25579.CrossRefPubMed
56.
Al-Romaih K, Somers GR, Bayani J, Hughes S, Prasad M, Cutz JC, Xue H, Zielenska M, Wang Y, Squire JA: Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation. Cancer Cell Int. 2007, 7: 14-10.1186/1475-2867-7-14.PubMedCentralCrossRefPubMed
57.
Vereecke L, Beyaert R, van Loo G: Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans. 2011, 39 (4): 1086-1091. 10.1042/BST0391086.CrossRefPubMed
58.
59.
Ayala R, Martinez-Lopez J, Gilsanz F: Acute myeloid leukemia and transcription factors: role of erythroid Kruppel-like factor (EKLF). Cancer Cell Int. 2012, 12 (1): 25-10.1186/1475-2867-12-25.PubMedCentralCrossRefPubMed
60.
Wu ZL, Song YQ, Shi YF, Zhu J: High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol. 2011, 4 (1): 31-10.1186/1756-8722-4-31.CrossRefPubMed
61.
Zheng H, Chen Y, Chen S, Niu Y, Yang L, Li B, Lu Y, Geng S, Du X, Li Y: Expression and distribution of PPP2R5C gene in leukemia. J Hematol Oncol. 2011, 4: 21-10.1186/1756-8722-4-21.PubMedCentralCrossRefPubMed
62.
Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L, Geng S, Du X, Li Y: Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2010, 3 (1): 44-10.1186/1756-8722-3-44.PubMedCentralCrossRefPubMed
Metadata
Title
The role of A20 in the pathogenesis of lymphocytic malignancy
Authors
Fan Zhang
Lijiang Yang
Yangqiu Li
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2012
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-12-44

Other articles of this Issue 1/2012

Cancer Cell International 1/2012 Go to the issue

Primary research

ZIP8 expression in human proximal tubule cells, human urothelial cells transformed by Cd+2 and As+3 and in specimens of normal human urothelium and urothelial cancer

Primary research

The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase

Primary research

Cellular damage and apoptosis along with changes in NF-kappa B expression were induced with contrast agent enhanced ultrasound in gastric cancer cells and hepatoma cells

Primary research

Analysis of volatile organic compounds released from human lung cancer cells and from the urine of tumor-bearing mice

Primary research

Caveolin-1 expression is elevated in claudin-low mammary tumor cells

Primary research

Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits